Translation Services for Life Sciences Companies

What are translation services for life sciences companies?

Translation services for life sciences companies convert regulated pharmaceutical, biotech, CRO and medical device content into other languages under ISO 17100, using life-sciences-qualified linguists, controlled terminology and a documented translate-edit-proofread workflow for MHRA, EMA and FDA submissions.

How much do life science translation services cost in the UK?

Life science translation services in the UK are priced from £30 per page or per word with volume tiering, with ISO 17100 TEP included; certified pharmaceutical translation starts at £30 per page, and MTPE for non-regulated content is priced lower against agreed post-editing effort.

Which life sciences sectors do translation services support?

Translation services support eight life sciences sectors: pharmaceuticals, biotechnology, medical devices, in-vitro diagnostics, contract research organisations, clinical research sites, digital health and healthtech, and public health bodies commissioning multilingual patient communications.

What document types do life science translation services handle?

Life science translation services handle six document families: clinical documentation (protocols, ICFs, CRFs), regulatory submissions (dossiers, CTAs, MAAs), medical device content (IFUs, SSCPs, UI strings), pharmacovigilance reports, scientific and medical affairs materials, and commercial content including patient-facing websites and HCP training.

How do life science translation companies ensure quality and regulatory compliance?

Life science translation companies ensure quality and regulatory compliance through five controls: ISO 17100 translate-edit-proofread workflow, ISO 27001 information security for patient data, life-sciences-qualified linguists with documented competence records, controlled terminology via translation memory and termbase, and named in-country clinical reviewers for device work.

How do life science translation services support MHRA, EMA and FDA submissions?

Life science translation services support MHRA, EMA and FDA submissions by producing eCTD-ready translations in module 1 country-specific formats, delivering EMA QRD-templated product information in the EU 24 official languages, and preparing MHRA UK-specific labelling for the dual Great Britain and Northern Ireland market post-Brexit.

Translation services for life sciences companies convert regulated pharmaceutical, biotech, CRO and medical device content into other languages under ISO 17100, using life-sciences-qualified linguists, controlled terminology and a documented translate-edit-proofread workflow for MHRA, EMA and FDA submissions.

How it works

Life science translation companies ensure quality and regulatory compliance through five controls: ISO 17100 translate-edit-proofread workflow, ISO 27001 information security for patient data, life-sciences-qualified linguists with documented competence records, controlled terminology via translation memory and termbase, and named in-country clinical reviewers for device work.

Complete guide

Regulated life sciences translation is a procurement and regulatory-affairs decision, not a marketing spend. UK-headquartered pharmaceutical, biotech, CRO and medical device organisations submit multilingual content to the MHRA, EMA and FDA under ISO 17100 governance — and the language service provider they appoint must meet that bar on day one.

Life science translation companies ensure quality and compliance through five interlocking controls: an ISO 17100 translate–edit–proofread workflow, ISO 27001 information security, life-sciences-qualified linguists with documented competence records, controlled terminology via translation memory and termbase, and named in-country clinical reviewers for device and patient-facing work. Each control addresses a specific failure mode — workflow errors, data breaches, unqualified linguists, terminology drift, and cultural non-equivalence — and all five must operate simultaneously for a submission to meet regulator expectations. Projects are handled in accordance with recognised quality standards throughout every stage of the translation lifecycle.

What does the ISO 17100 TEP workflow look like in practice?

The ISO 17100 TEP workflow runs in four sequential stages, each with a defined accountable role: translation by a qualified life-sciences linguist, independent revision by a second linguist, in-country review by a named clinical reviewer where the client or regulator requires it, and final proofreading in layout before regulator-ready delivery. No stage can be skipped or merged — the independence of the revision step is what ISO 17100 certification requires and what regulators expect to see evidenced in a quality record.

1. Translation by a life-sciences-qualified linguist who self-checks the output against the client termbase and source text before handover.
2. Bilingual revision by an independent second linguist — the mandatory ISO 17100 gate that catches errors in meaning, terminology, register and regulatory phrasing.
3. In-country clinical review by a named reviewer for device IFUs, patient information leaflets and informed consent forms where clinical accuracy and cultural appropriateness must be verified simultaneously.
4. Final proofreading in the delivered layout, with automated QA checks on numeric consistency, drug-name rendering and formatting against the eCTD or device technical file template.

How are translation memory, termbase and glossary managed?

Translation memory stores every approved segment at sentence level for reuse across future projects, enforcing consistency automatically rather than relying on individual linguist recall. The termbase enforces client-approved target terms for drug names, device components and regulatory phrasing — the same approved term is applied every time, in every language, across every document in a submission suite. The client-approved glossary is maintained under version control so the same concept never appears with two different renderings within one dossier, label set or clinical site file. Translation memory ownership is vested in the client under the framework agreement, so the full reuse benefit accumulates with the sponsor rather than the service provider.

How is patient data protected under ISO 27001?

Patient data is protected under ISO 27001 through role-based access controls, encrypted file transfer, segregated project environments, signed confidentiality agreements with every linguist and project manager, and full audit logging that meets sponsor GCP inspection requirements and UK GDPR obligations under the Data Protection Act 2018. Life sciences documents contain confidential product, clinical, commercial and patient-related information, and secure workflows must be demonstrable — not merely asserted — when a regulatory inspector or data protection officer reviews the translation supply chain. Every linguist engaged on a regulated project signs a non-disclosure agreement before receiving any project material.

Why does scientific precision matter more in life science translation than in other fields?

A single mistranslated dosage, contraindication or assay parameter can trigger regulatory rejection, patient harm or product recall, which is why life science translation carries a standard of care that no general language service can replicate. Life sciences linguists combine native-level fluency in the target language with deep subject-matter knowledge — a degree-level qualification in medicine, pharmacology, biomedical engineering or biotechnology — to render technical terminology with zero ambiguity across every target language. Precision is not a quality aspiration; it is a regulatory requirement, and it is enforced at every stage of the TEP workflow.

Life science translation is technically and operationally more demanding than any other translation discipline because the consequences of failure extend beyond a poor customer experience to regulatory rejection, patient harm and product recall. The five key challenges are terminology drift, per-country regulatory divergence, tight submission windows, machine translation temptation on safety-critical content, and cross-cultural equivalence of patient-reported outcomes — and each requires a specific, documented countermeasure rather than a generic quality commitment.

• Terminology drift across a submission suite — A dossier can run to hundreds of documents across dozens of languages, and without a version-controlled termbase and translation memory enforced at segment level, the same drug name or device component descriptor will render differently across documents. Drift of this kind triggers regulator queries and can delay market authorisation. The countermeasure is a client-owned termbase and TM applied to every project from day one.
• Per-country regulatory divergence within the EU — MDR, IVDR and CTR establish EU-wide frameworks, but national competent authorities apply additional labelling, formatting and language requirements that vary by member state. A device IFU that satisfies the German notified body may require structural amendments for the French or Polish market. In-country reviewers with national regulatory expertise resolve these divergences before submission rather than after rejection.
• Tight submission windows that clash with TEP capacity — Regulatory timelines are fixed by the regulator, not the sponsor, and a clinical trial application, label variation or post-market safety update may arrive with a 48-hour turnaround requirement. ISO 17100 mandates a three-stage workflow that cannot be compressed by skipping revision. Retained linguist teams and early project intake are the only reliable solutions — a provider without reserved capacity cannot guarantee throughput of 1,500–2,000 words per linguist per day on demand.
• Machine translation temptation on safety-critical content — MT is faster and cheaper, and the pressure to use it on IFUs, PILs and informed consent forms is real. The policy is unambiguous: MT is not used on any regulated or patient-facing content, because current neural MT systems cannot guarantee the accuracy that patient safety and regulatory acceptance require. The risk of a single dosage error in an MT-generated patient leaflet far exceeds any cost saving.
• Cross-cultural equivalence of patient-reported outcomes — PRO instruments such as quality-of-life questionnaires and symptom diaries must capture the same clinical construct across every target language, not merely translate words. Linguistic validation — including forward translation, back-translation, reconciliation, cognitive debriefing with target-population participants, and psychometric review — is required by EMA, FDA and MHRA to demonstrate equivalence. Patient and user clarity is a regulatory requirement, not a translation quality goal, and multilingual audiences must be able to understand instructions, risks, benefits and next steps in their own language with full accuracy and cultural appropriateness.

Addressing all five challenges simultaneously requires a provider with documented quality processes, retained subject-matter linguists, secure content-handling infrastructure and a strict MT policy for regulated content — not a general language service applying a life sciences label to standard commercial workflows.

Frequently asked questions cover pricing, turnaround, MT policy, regulatory acceptance, language pairs, and translator qualifications — the six topics UK procurement and regulatory affairs teams evaluate before appointing a language service provider.